Payment overview · 2025
General Payments
$1,003.85
67 reported records · 12 companies
Healthcare provider profile · identity verified
Darrel L. Stout, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · EDMOND, OK · NPI 1356362073
Verified facts
What the public records show
CMS Open Payments records show Darrel L. Stout, M.D. received $1,003.85 in general payments during 2025 across 67 reported records.
PFIZER INC. accounted for 30.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $309.46 | 30.8% | 29 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $227.32 | 22.6% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $199.70 | 19.9% | 19 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $48.39 | 4.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $48.22 | 4.8% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $37.90 | 3.8% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $32.83 | 3.3% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $27.02 | 2.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.78 | 2.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.51 | 1.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.95 | 1.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.77 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,003.85 | 67 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $195.24 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $181.45 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $118.94 | 7 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $118.94 | 7 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $118.94 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $110.01 | 16 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $109.71 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $87.11 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $80.51 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $80.51 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $72.31 | 7 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $48.39 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $48.22 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $37.90 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $32.83 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $27.02 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.78 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.99 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 50 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 66 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
66 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
50 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 432 | 134 |
| Levothyroxine Sodium | Levothyroxine Sodium | 351 | 101 |
| Alprazolam | Alprazolam | 341 | 60 |
| Lisinopril | Lisinopril | 300 | 92 |
| Meloxicam | Meloxicam | 274 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 229 | 67 |
| Omeprazole | Omeprazole | 216 | 62 |
| Gabapentin | Gabapentin | 215 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 213 | 67 |
| Tramadol Hcl | Tramadol Hcl | 198 | 55 |
| Prednisone | Prednisone | 184 | 135 |
| Losartan Potassium | Losartan Potassium | 174 | 55 |
| Metformin Hcl Er | Metformin Hcl | 170 | 58 |
| Trazodone Hcl | Trazodone Hcl | 164 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 159 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 159 | 44 |
| Furosemide | Furosemide | 146 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 138 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 134 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 129 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 121 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 119 | 32 |
| Alendronate Sodium | Alendronate Sodium | 113 | 28 |
| Simvastatin | Simvastatin | 109 | 31 |
| Diclofenac Potassium | Diclofenac Potassium | 107 | 53 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 104 | 35 |
| Allopurinol | Allopurinol | 97 | 28 |
| Atenolol | Atenolol | 89 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 88 | 29 |
| Celecoxib | Celecoxib | 80 | 27 |
| Montelukast Sodium | Montelukast Sodium | 80 | 25 |
| Donepezil Hcl | Donepezil Hcl | 79 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 77 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 77 | 24 |
| Metformin Hcl | Metformin Hcl | 75 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 69 | 42 |
| Bupropion Hcl Sr | Bupropion Hcl | 67 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 66 | 20 |
| Ozempic | Semaglutide | 66 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 66 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 64 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 23 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 64 | 17 |
| Ezetimibe | Ezetimibe | 63 | 16 |
| Finasteride | Finasteride | 59 | 11 |
| Potassium Chloride | Potassium Chloride | 59 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 18 |
| Pregabalin | Pregabalin | 58 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 57 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 18 |
| Temazepam | Temazepam | 56 | suppressed |
| Estradiol | Estradiol | 55 | 14 |
| Memantine Hcl | Memantine Hcl | 55 | 11 |
| Bupropion Xl | Bupropion Hcl | 52 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 14 |
| Spironolactone | Spironolactone | 52 | 17 |
| Synthroid | Levothyroxine Sodium | 51 | suppressed |
| Eliquis | Apixaban | 50 | 19 |
| Mounjaro | Tirzepatide | 50 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 50 | 14 |
| Ibuprofen | Ibuprofen | 49 | 15 |
| Januvia | Sitagliptin Phosphate | 49 | 15 |
| Valacyclovir | Valacyclovir Hcl | 49 | 23 |
| Famotidine | Famotidine | 48 | 16 |
| Glimepiride | Glimepiride | 48 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 19 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 47 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 47 | 15 |
| Irbesartan | Irbesartan | 47 | 12 |
| Jardiance | Empagliflozin | 47 | 15 |
| Clonazepam | Clonazepam | 46 | suppressed |
| Diazepam | Diazepam | 46 | 16 |
| Azithromycin | Azithromycin | 45 | 34 |
| Doxepin Hcl | Doxepin Hcl | 45 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 45 | 14 |
| Ondansetron Odt | Ondansetron | 42 | 21 |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 41 | suppressed |
| Carvedilol | Carvedilol | 40 | 15 |
| Fluconazole | Fluconazole | 40 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 38 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 36 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 35 | suppressed |
| Lorazepam | Lorazepam | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 12 |
| Nystatin | Nystatin | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 25 | 13 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 25 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 23 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Premarin | Estrogens, Conjugated | 23 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Etodolac | Etodolac | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 17 |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 18 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Dulera | Mometasone/Formoterol | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 12 |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Alprazolam Er | Alprazolam | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Progesterone | Progesterone, Micronized | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,003.85 · 67 records | PFIZER INC. | ABRYSVO, ACCRUFER, AIRSUPRA, CAPLYTA, COMIRNATY, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, REXULTI, REZDIFFRA, Rybelsus, SHINGRIX, UBRELVY, VRAYLAR, Veozah, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error